Cargando…
Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials
PURPOSE: To investigate the efficacy and safety of saffron in the treatment of major depressive disorder (MDD) in comparison to placebo and synthetic antidepressants. PATIENTS AND METHODS: We conducted a systematic search in several electronic databases as well as manual search in bibliographies of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967372/ https://www.ncbi.nlm.nih.gov/pubmed/29849461 http://dx.doi.org/10.2147/NDT.S157550 |
_version_ | 1783325603280191488 |
---|---|
author | Yang, Xiangying Chen, Xiaolu Fu, Yixiao Luo, Qinghua Du, Lian Qiu, Haitang Qiu, Tian Zhang, Li Meng, Huaqing |
author_facet | Yang, Xiangying Chen, Xiaolu Fu, Yixiao Luo, Qinghua Du, Lian Qiu, Haitang Qiu, Tian Zhang, Li Meng, Huaqing |
author_sort | Yang, Xiangying |
collection | PubMed |
description | PURPOSE: To investigate the efficacy and safety of saffron in the treatment of major depressive disorder (MDD) in comparison to placebo and synthetic antidepressants. PATIENTS AND METHODS: We conducted a systematic search in several electronic databases as well as manual search in bibliographies of relevant studies. We included randomized controlled trials that investigated the efficacy and safety of saffron for treating MDD in adults in comparison to either placebo or synthetic antidepressants. Primary outcome was change in scores on depressive symptoms from baseline. Secondary outcomes included remission rate, response rate, and drop-out rate for all reasons. We chose a random-effects model in order to obtain more conservative results. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated as the overall effect index by inverse variance models. RESULTS: Seven studies were included in this meta-analysis. Overall quality of these included studies was moderate. As for the primary outcome, saffron showed more improvements in depression symptoms when compared with placebo, with an SMD of −1.22 (95% CI −1.94, −0.49, P=0.001). Meanwhile, saffron was as effective as synthetic antidepressants, with an SMD of 0.16 (95% CI −0.25, 0.57, P=0.44). Moderate heterogeneity existed in our analysis. Through subgroup analyses, we found that treatment dosage and duration, types of synthetic antidepressants administered in the comparison group, and outcome measures could explain most of the variance. No differences were found in remission rate, response rate, or drop-out rate. CONCLUSION: Saffron was effective in the treatment of MDD and had comparable efficacy to synthetic antidepressants. Saffron was also a safe drug without serious adverse events reported. |
format | Online Article Text |
id | pubmed-5967372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-59673722018-05-30 Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials Yang, Xiangying Chen, Xiaolu Fu, Yixiao Luo, Qinghua Du, Lian Qiu, Haitang Qiu, Tian Zhang, Li Meng, Huaqing Neuropsychiatr Dis Treat Original Research PURPOSE: To investigate the efficacy and safety of saffron in the treatment of major depressive disorder (MDD) in comparison to placebo and synthetic antidepressants. PATIENTS AND METHODS: We conducted a systematic search in several electronic databases as well as manual search in bibliographies of relevant studies. We included randomized controlled trials that investigated the efficacy and safety of saffron for treating MDD in adults in comparison to either placebo or synthetic antidepressants. Primary outcome was change in scores on depressive symptoms from baseline. Secondary outcomes included remission rate, response rate, and drop-out rate for all reasons. We chose a random-effects model in order to obtain more conservative results. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated as the overall effect index by inverse variance models. RESULTS: Seven studies were included in this meta-analysis. Overall quality of these included studies was moderate. As for the primary outcome, saffron showed more improvements in depression symptoms when compared with placebo, with an SMD of −1.22 (95% CI −1.94, −0.49, P=0.001). Meanwhile, saffron was as effective as synthetic antidepressants, with an SMD of 0.16 (95% CI −0.25, 0.57, P=0.44). Moderate heterogeneity existed in our analysis. Through subgroup analyses, we found that treatment dosage and duration, types of synthetic antidepressants administered in the comparison group, and outcome measures could explain most of the variance. No differences were found in remission rate, response rate, or drop-out rate. CONCLUSION: Saffron was effective in the treatment of MDD and had comparable efficacy to synthetic antidepressants. Saffron was also a safe drug without serious adverse events reported. Dove Medical Press 2018-05-21 /pmc/articles/PMC5967372/ /pubmed/29849461 http://dx.doi.org/10.2147/NDT.S157550 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Yang, Xiangying Chen, Xiaolu Fu, Yixiao Luo, Qinghua Du, Lian Qiu, Haitang Qiu, Tian Zhang, Li Meng, Huaqing Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
title | Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
title_full | Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
title_fullStr | Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
title_full_unstemmed | Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
title_short | Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
title_sort | comparative efficacy and safety of crocus sativus l. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967372/ https://www.ncbi.nlm.nih.gov/pubmed/29849461 http://dx.doi.org/10.2147/NDT.S157550 |
work_keys_str_mv | AT yangxiangying comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT chenxiaolu comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT fuyixiao comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT luoqinghua comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT dulian comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT qiuhaitang comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT qiutian comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT zhangli comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT menghuaqing comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials |